公开(公告)号：WO2007035576A3

公开(公告)日：2007-06-14

申请号：PCT/US2006036193

申请日：2006-09-15

Applicant: NORTHERN ADVANCEMENT CT FOR SC ,  HAKOMORI SENITIROH ,  TAYA MINORU ,  SU FENGYU ,  XU CHUNYE ,  HANDA KAZUKO ,  MURAYAMA KIMIE ,  FUJIMURA TSUTOMU

Inventor： HAKOMORI SENITIROH ,  TAYA MINORU ,  SU FENGYU ,  XU CHUNYE ,  HANDA KAZUKO ,  MURAYAMA KIMIE ,  FUJIMURA TSUTOMU

IPC: G01N33/53 ,  C12N11/00 ,  C12Q1/00

CPC classification number: G01N33/57423 ,  B82Y15/00 ,  B82Y30/00 ,  B82Y40/00 ,  G01N33/54373 ,  G01N33/57415 ,  G01N33/57434 ,  G01N33/57446 ,  G01N33/57492

Abstract: The present invention provides an SPR system and corresponding methods of use, for determining the presence or concentration of tumor-associated antigens in cancer patient samples. The SPR system may have multiple channels, with each channel having operably affixed thereto an antibody specific for a tumor-associated antigen, so as to allow detection of multiple tumor-associated antigens simultaneously. When a biological sample from a patient is applied to the SPR system, the presence of two or more tumor-associated antigens can be determined by measuring an SPR signal shift from each channel. The SPR system may detect the presence or concentration of a tumor-associated carbohydrate antigen, where the sensor surface contains affixed thereto an antibody specific for the glycosyl epitope, as well as an antibody specific for the polypeptide to which the carbohydrate antigen is naturally associated in cancer patients.

Abstract translation: 本发明提供了用于确定癌症患者样品中肿瘤相关抗原的存在或浓度的SPR系统和相应的使用方法。 SPR系统可以具有多个通道，每个通道可操作地附着有对肿瘤相关抗原特异性的抗体，从而允许同时检测多种肿瘤相关抗原。 当将来自患者的生物样品应用于SPR系统时，可以通过测量来自每个通道的SPR信号移位来确定两种或更多种肿瘤相关抗原的存在。 SPR系统可检测肿瘤相关糖抗原的存在或浓度，其中传感器表面含有附着有对糖基表位特异性的抗体以及对糖抗原天然相关的多肽具有特异性的抗体 癌症患者。

公开(公告)号：WO2005098434A3

公开(公告)日：2007-01-11

申请号：PCT/US2005010221

申请日：2005-03-25

Applicant: NORTHERN ADVANCEMENT CT FOR SC ,  HAKOMORI SENITIROH ,  SAITO SEIICHI

Inventor： HAKOMORI SENITIROH ,  SAITO SEIICHI

IPC: G01N33/574 ,  G01N33/53 ,  G01N33/567

CPC classification number: G01N33/57434 ,  G01N33/5308 ,  G01N2400/00

Abstract: A novel carbohydrate antigen, ß1,4-GalNAc-disialyl-Lc 4 , defined by monoclonal antibody RM2, is expressed in human prostate cancer, but not in benign prostate hypertrophy (BPH) or normal prostate gland. Monoclonal antibody RM2 or other antibodies with similar specificity are useful for diagnosis of prostate cancer by immunohistology of biopsy samples, specifications from a total prostatectomy, and quantitative determination of RM2 antigen in sera of patients.

Abstract translation: 由单克隆抗体RM2定义的新型碳水化合物抗原β1,4-GalNAc-二唾液酸-Lc 4 S在人前列腺癌中表达，但不在良性前列腺肥大（BPH）或正常前列腺中表达。 具有相似特异性的单克隆抗体RM2或其他抗体可用于通过活组织检查样品的免疫组织化学检查，前列腺切除术的规格和患者血清中RM2抗原的定量测定来诊断前列腺癌。

公开(公告)号：AU2005231081A1

公开(公告)日：2005-10-20

申请号：AU2005231081

申请日：2005-03-25

Applicant: NORTHERN ADVANCEMENT CT FOR SC

Inventor： HAKOMORI SENITIROH ,  SAITO SEIICHI

IPC: G01N33/53 ,  G01N33/567 ,  G01N33/574

Abstract: A novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc 4 , defined by monoclonal antibody RM2, is expressed in human prostate cancer, but not in benign prostate hypertrophy (BPH) or normal prostate gland. Monoclonal antibody RM2 or other antibodies with similar specificity are useful for diagnosis of prostate cancer by immunohistology of biopsy samples, specifications from a total prostatectomy, and quantitative determination of RM2 antigen in sera of patients.

公开(公告)号：CA2559525A1

公开(公告)日：2005-10-20

申请号：CA2559525

申请日：2005-03-25

Applicant: NORTHERN ADVANCEMENT CT FOR SC

Inventor： SAITO SEIICHI ,  HAKOMORI SENITIROH

IPC: G01N33/53 ,  G01N33/567 ,  G01N33/574

Abstract: A novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc 4 , defined by monoclonal antibody RM2, is expressed in human prostate cancer, but not in benign prostate hypertrophy (BPH) or normal prostate gland. Monoclonal antibody RM2 or other antibodies with similar specificity are useful for diagnosis of prostate cancer by immunohistology of biopsy samples, specifications from a total prostatectomy, and quantitative determination of RM2 antigen in sera of patients.